Rigel Pharma: FDA To Review NDA For TAVALISSE - Quick Facts


Shutterstock photo

(RTTNews.com) - Rigel Pharmaceuticals, Inc. ( RIGL ) announced the U.S. FDA has filed its New Drug Application for the use of TAVALISSE (fostamatinib disodium) in patients with chronic or persistent immune thrombocytopenia. The NDA submission is supported by data from the Phase 3 clinical program for fostamatinib in ITP, which was comprised of three studies, two randomized placebo-controlled studies, and an open-label extension study.

Rigel expects the action date for the FDA to complete its review will be April 17, 2018, under PDUFA. The FDA previously granted Orphan Drug designation to TAVALISSE for the treatment of patients with immune thrombocytopenia.

For comments and feedback: contact editorial@rttnews.com




This article appears in: World Markets , Stocks
Referenced Symbols: RIGL


More from RTT News

Subscribe






See headlines for RIGL

Follow on:








Research Brokers before you trade

Want to trade FX?